Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | May 23, 2019 | May 24, 2019 |
| Quanterix CorpQTRX · Entity 6649 | Director | January 02, 2024 | January 04, 2024 |
| QuidelOrtho CorpQDEL · Entity 4986 | President and CEO | May 15, 2026 | May 19, 2026 |
| Rockley Photonics Holdings LtdRKLY · Entity 122956 | Director | May 17, 2022 | August 30, 2022 |
| Talis Biomedical CorpTLIS · Entity 87664 | Director · President and CEO | December 01, 2021 | December 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date May 23, 2019 · Filed May 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 130,745 |
Ending reported balance
After 2019-05-23 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2019-05-23 · Exercise / conversion · Acquired 165,000 · Balance 295,745 Row 2 · 2019-05-23 · Exercise / conversion · Acquired 175,164 · Balance 470,909 Row 3 · 2019-05-23 · Exercise / conversion · Acquired 53,163 · Balance 524,072 Row 4 · 2019-05-23 · Exercise / conversion · Acquired 56,735 · Balance 580,807 Row 5 · 2019-05-23 · Sale · Disposed 450,062 · Balance 130,745 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.50 to $75.70, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.94 · Expires 2023-02-14 | Direct | 0 |
Reported balance
After 2019-05-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-05-23 · Exercise / conversion · Disposed 165,000 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.12 · Expires 2024-02-20 | Direct | 0 |
Reported balance
After 2019-05-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-05-23 · Exercise / conversion · Disposed 175,164 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.00 · Expires 2025-02-19 | Direct | 120,000 |
Reported balance
After 2019-05-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-05-23 · Exercise / conversion · Disposed 53,163 · Balance 120,000 F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.40 · Expires 2026-02-18 | Direct | 300,000 |
Reported balance
After 2019-05-23 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-05-23 · Exercise / conversion · Disposed 56,735 · Balance 300,000 F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.50 to $75.70, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Quanterix Corp
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,049 |
Reported balance
After 2024-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-01-02 · Grant · Acquired 2,947 · Balance 19,049 F1: Represents restricted stock units that vest as to 100% of the shares on December 31, 2024 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2: Includes 19,049 restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.15 · Expires 2034-01-02 | Direct | 6,412 |
Reported balance
After 2024-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-02 · Grant · Acquired 6,412 · Balance 6,412 F3: Represents non-qualified stock option to purchase 6,412 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest as to 100% of the shares on December 31, 2024 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
F2: Includes 19,049 restricted stock units.
F3: Represents non-qualified stock option to purchase 6,412 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy.
QuidelOrtho Corp
Report date May 15, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,649 |
Ending reported balance
After 2026-05-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-15 · Grant · Acquired 20,759 · Balance 45,901 F1: Reflects release of restricted stock units that were previously reported on a Form 3. Row 2 · 2026-05-15 · Tax withholding · Disposed 10,252 · Balance 35,649 F2: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 20,759 |
Reported balance
After 2026-05-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-15 · Exercise / conversion · Disposed 20,759 · Balance 20,759 F3: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4: 20,759 shares vested on each of May 15, 2025 and May 15, 2026; the remaining 20,759 shares will vest on May 15, 2027. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 40,073 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 40,073 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects release of restricted stock units that were previously reported on a Form 3.
F2: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units.
F3: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F4: 20,759 shares vested on each of May 15, 2025 and May 15, 2026; the remaining 20,759 shares will vest on May 15, 2027.
Rockley Photonics Holdings Ltd
Report date May 17, 2022 · Filed August 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 65,322 |
Reported balance
After 2022-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-17 · Grant · Acquired 65,322 · Balance 65,322 F1: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control.
Talis Biomedical Corp
Report date December 01, 2021 · Filed December 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.47 · Expires 2031-11-30 | Direct | 750,000 |
Reported balance
After 2021-12-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-01 · Grant · Acquired 750,000 · Balance 750,000 F1: 20% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date and 1/60th of the shares underlying this option shall vest monthly thereafter over 48 months. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 625,000 |
Reported balance
After 2021-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-01 · Grant · Acquired 625,000 · Balance 625,000 F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock upon vesting. F3: 20% of the shares shall vest on the first annual anniversary of the vesting commencement date and the balance of the shares will vest in a series of four equal successive annual installments. |
Filing footnotes · ownership attribution and instrument terms
F1: 20% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date and 1/60th of the shares underlying this option shall vest monthly thereafter over 48 months.
F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock upon vesting.
F3: 20% of the shares shall vest on the first annual anniversary of the vesting commencement date and the balance of the shares will vest in a series of four equal successive annual installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 19, 2026 20:05 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units · Derivative | 20,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001492289-26-000008 · wk-form4_1779221140.xml · derivative · entry 4 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,759 Underlying: Common Stock · 20,759 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 20,759 shares vested on each of May 15, 2025 and May 15, 2026; the remaining 20,759 shares will vest on May 15, 2027. F4 · derivative.expiration_date: 20,759 shares vested on each of May 15, 2025 and May 15, 2026; the remaining 20,759 shares will vest on May 15, 2027. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:05 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Tax withholdingCommon Stock | 10,252 | $10.32 | $105,800.64 |
DisclosureSEC source: 0001492289-26-000008 · wk-form4_1779221140.xml · nonDerivative · entry 2 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,649 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:05 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 20,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001492289-26-000008 · wk-form4_1779221140.xml · nonDerivative · entry 1 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,901 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 3. Read SEC document |
| February 13, 2026 Filed Feb 13, 2026 15:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | PurchaseCommon Stock | 10,540 | $23.59 | $248,660.73 |
DisclosureSEC source: 0001492289-26-000006 · wk-form4_1770997380.xml · nonDerivative · entry 1 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 40,073 F1 · price: The weighted average purchase price of these transactions was $23.5921 per share, with a range of $23.4200 to $23.9400 per share. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares purchased at each separate price. Read SEC document |
| January 30, 2026 Filed Feb 4, 2026 00:48 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 213,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001492289-26-000004 · wk-form4_1770166116.xml · derivative · entry 1 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,470 Underlying: Common Stock · 213,470 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: 71,156 shares will vest on January 30, 2027; the remaining 142,314 shares will vest in equal installments on January 30, 2028 and January 30, 2029. F2 · derivative.expiration_date: 71,156 shares will vest on January 30, 2027; the remaining 142,314 shares will vest in equal installments on January 30, 2028 and January 30, 2029. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 00:04 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units · Derivative | 21,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001492289-26-000002 · wk-form4_1770077088.xml · derivative · entry 4 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,892 Underlying: Common Stock · 21,446 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 21,446 shares vested on January 29, 2026; the remaining 42,892 shares will vest in equal installments on January 29, 2027 and January 29, 2028. F4 · derivative.expiration_date: 21,446 shares vested on January 29, 2026; the remaining 42,892 shares will vest in equal installments on January 29, 2027 and January 29, 2028. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 00:04 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Tax withholdingCommon Stock | 7,755 | $27.41 | $212,564.55 |
DisclosureSEC source: 0001492289-26-000002 · wk-form4_1770077088.xml · nonDerivative · entry 2 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,142 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 00:04 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 21,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001492289-26-000002 · wk-form4_1770077088.xml · nonDerivative · entry 1 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,897 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 21:16 UTC | QuidelOrtho Corp QDEL · Entity 4986 | PurchaseCommon Stock | 23,500 | $21.34 | $501,576.95 |
DisclosureSEC source: 0001492289-25-000006 · wk-form4_1763673411.xml · nonDerivative · entry 1 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 29,533 F1 · price: The weighted average purchase price for these transactions was $21.3437 per share, with a range of $20.91 to $21.72 per share. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:18 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units · Derivative | 20,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000059 · wk-form4_1747685890.xml · derivative · entry 4 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,518 Underlying: Common Stock · 20,759 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 20,759 shares vested on May 15, 2025; 20,759 shares will vest on May 15, 2026 and 20,759 shares will vest on May 15, 2027. F4 · derivative.expiration_date: 20,759 shares vested on May 15, 2025; 20,759 shares will vest on May 15, 2026 and 20,759 shares will vest on May 15, 2027. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:18 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Tax withholdingCommon Stock | 9,308 | $33.03 | $307,443.24 |
DisclosureSEC source: 0001906324-25-000059 · wk-form4_1747685890.xml · nonDerivative · entry 2 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,451 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:18 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 20,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000059 · wk-form4_1747685890.xml · nonDerivative · entry 1 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,759 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 23:18 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 52,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000005 · wk-form4_1738365523.xml · derivative · entry 1 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,390 Underlying: Common Stock · 52,390 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: 34,926 shares will vest in equal installments on January 29, 2026 and January 29, 2027; the remaining 17,464 shares will vest on January 29, 2028. F2 · derivative.expiration_date: 34,926 shares will vest in equal installments on January 29, 2026 and January 29, 2027; the remaining 17,464 shares will vest on January 29, 2028. Read SEC document |
| January 29, 2025 Filed Feb 5, 2025 22:40 UTC Amendment | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 64,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000023 · wk-form4a_1738795227.xml · derivative · entry 1 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,338 Underlying: Common Stock · 64,338 shares Expires not disclosed F1 · security: The Form 4 originally filed on January 31, 2025 is being amended to report the correct number of shares underlying the grant of restricted stock units to the reporting person on January 29, 2025. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: 64,338 shares will vest in equal installments on January 29, 2026, January 29, 2027 and January 29, 2028. F3 · derivative.expiration_date: 64,338 shares will vest in equal installments on January 29, 2026, January 29, 2027 and January 29, 2028. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:12 UTC | QuidelOrtho Corp QDEL · Entity 4986 | PurchaseCommon Stock | 6,033 | $41.42 | $249,878.41 |
DisclosureSEC source: 0001906324-24-000072 · wk-form4_1734124371.xml · nonDerivative · entry 1 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 6,033 Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:09 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 6,412 | $0.00 Strike: $27.15 | $0.00 |
DisclosureSEC source: 0001562180-24-000231 · primarydocument.xml · derivative · entry 2 Blaser Brian J · CIK 0001492289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,412 Underlying: Common Stock · 6,412 shares Expires 2034-01-02 F3 · shares: Represents non-qualified stock option to purchase 6,412 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:09 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000231 · primarydocument.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,049 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2024 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 19,049 restricted stock units. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 21:45 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (right to buy) · Derivative | 24,153 | $0.00 Strike: $12.94 | $0.00 |
DisclosureSEC source: 0001562180-23-000292 · primarydocument.xml · derivative · entry 2 Blaser Brian J · CIK 0001492289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,153 Underlying: Common Stock · 24,153 shares Expires 2033-01-06 F3 · derivative.exercise_date: The option vests as to one-third of the shares on January 6, 2024, and the remaining two-thirds of the shares vest monthly thereafter over two years in 24 successive equal installments. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 21:45 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 16,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000292 · primarydocument.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,102 F1 · shares: Represents shares of stock issuable on vesting of restricted stock units. The restricted stock units vest as to one-third of shares on each of January 6, 2024, January 6, 2025 and January 6, 2026. F2 · balance_after: Includes 16,102 restricted stock units. Read SEC document |
| May 17, 2022 Filed Aug 30, 2022 16:23 UTC | Rockley Photonics Holdings Ltd RKLY · Entity 122956 | GrantRestricted Stock Unit · Derivative | 65,322 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001852117-22-000304 · wf-form4_166189099161360.xml · derivative · entry 1 Blaser Brian J · CIK 0001492289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,322 Underlying: Ordinary Share · 65,322 shares Expires not disclosed F1 · derivative.exercise_date: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control. F1 · derivative.expiration_date: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control. Read SEC document |
| May 16, 2022 Filed Jun 8, 2022 18:24 UTC | Rockley Photonics Holdings Ltd RKLY · Entity 122956 | Exercise / conversionRestricted Stock Unit · Derivative | 7,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001852117-22-000204 · wf-form4_165472704824942.xml · derivative · entry 2 Blaser Brian J · CIK 0001492289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,667 Underlying: Ordinary Share · 7,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each Restricted Stock Unit converted into one Ordinary Share effective 5/16/2022 F1 · derivative.expiration_date: Each Restricted Stock Unit converted into one Ordinary Share effective 5/16/2022 Read SEC document |
| May 16, 2022 Filed Jun 8, 2022 18:24 UTC | Rockley Photonics Holdings Ltd RKLY · Entity 122956 | Exercise / conversionOrdinary Share | 7,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001852117-22-000204 · wf-form4_165472704824942.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,393 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2022 Filed Mar 18, 2022 21:28 UTC | Rockley Photonics Holdings Ltd RKLY · Entity 122956 | PurchaseOrdinary Share | 47,060 | $4.19 | $197,369.64 |
DisclosureSEC source: 0001852117-22-000109 · wf-form4_164765331192889.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Read SEC document |
| March 18, 2022 Filed Mar 25, 2022 18:10 UTC Amendment | Rockley Photonics Holdings Ltd RKLY · Entity 122956 | PurchaseOrdinary Share | 47,060 | $4.19 | $197,369.64 |
DisclosureSEC source: 0001852117-22-000128 · wf-form4a_164824622180467.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,060 Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 22:04 UTC | Talis Biomedical Corp TLIS · Entity 87664 | GrantRestricted Stock Units · Derivative | 625,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-067642 · doc4.xml · derivative · entry 2 Blaser Brian J · CIK 0001492289 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,000 Underlying: Common Stock · 625,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock upon vesting. F3 · derivative.exercise_date: 20% of the shares shall vest on the first annual anniversary of the vesting commencement date and the balance of the shares will vest in a series of four equal successive annual installments. F3 · derivative.expiration_date: 20% of the shares shall vest on the first annual anniversary of the vesting commencement date and the balance of the shares will vest in a series of four equal successive annual installments. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 22:04 UTC | Talis Biomedical Corp TLIS · Entity 87664 | GrantStock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001209191-21-067642 · doc4.xml · derivative · entry 1 Blaser Brian J · CIK 0001492289 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2031-11-30 F1 · derivative.exercise_date: 20% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date and 1/60th of the shares underlying this option shall vest monthly thereafter over 48 months. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 15:58 UTC | Rockley Photonics Holdings Ltd RKLY · Entity 122956 | GrantRestricted Stock Unit · Derivative | 22,000 | $7.14 Strike: $0.00 | $157,080.00 |
DisclosureSEC source: 0001852117-21-000046 · wf-form4_163475989654817.xml · derivative · entry 1 Blaser Brian J · CIK 0001492289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Ordinary Share · 22,000 shares Expires not disclosed F1 · derivative.exercise_date: One third of the RSUs shall vest on the earlier of August 11, 2022 or the next annual shareholders' meeting, and in each of the next two calendar years following the year of the initial vesting date, an additional one third shall vest on the earlier of the 12-month anniversary of the prior annual shareholders' meeting or the current year annual shareholder' meeting, subject to acceleration upon a change in control. F1 · derivative.expiration_date: One third of the RSUs shall vest on the earlier of August 11, 2022 or the next annual shareholders' meeting, and in each of the next two calendar years following the year of the initial vesting date, an additional one third shall vest on the earlier of the 12-month anniversary of the prior annual shareholders' meeting or the current year annual shareholder' meeting, subject to acceleration upon a change in control. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 56,735 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · derivative · entry 9 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common shares · 56,735 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 53,163 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · derivative · entry 8 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common shares · 53,163 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 175,164 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · derivative · entry 7 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 175,164 shares Expires 2024-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 165,000 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · derivative · entry 6 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 165,000 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 450,062 | $75.52 | $33,988,727.25 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · nonDerivative · entry 5 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,745 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.50 to $75.70, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 56,735 | $38.40 | $2,178,624.00 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · nonDerivative · entry 4 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 53,163 | $47.00 | $2,498,661.00 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · nonDerivative · entry 3 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 175,164 | $39.12 | $6,852,415.68 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · nonDerivative · entry 2 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 165,000 | $34.94 | $5,765,100.00 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,177 | $78.21 | $92,053.17 |
DisclosureSEC source: 0001179110-19-003109 · edgar.xml · nonDerivative · entry 10 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,745 Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,736 | $78.21 | $448,618.30 |
DisclosureSEC source: 0001179110-19-003109 · edgar.xml · nonDerivative · entry 9 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,922 Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,100 | $78.22 | $86,042.00 |
DisclosureSEC source: 0001179110-19-003109 · edgar.xml · nonDerivative · entry 8 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,658 Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $78.22 | $23,466.30 |
DisclosureSEC source: 0001179110-19-003109 · edgar.xml · nonDerivative · entry 7 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,758 Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,900 | $78.23 | $148,637.00 |
DisclosureSEC source: 0001179110-19-003109 · edgar.xml · nonDerivative · entry 6 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,058 Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,642 | $78.24 | $284,950.08 |
DisclosureSEC source: 0001179110-19-003109 · edgar.xml · nonDerivative · entry 5 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,958 Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $78.24 | $46,944.60 |
DisclosureSEC source: 0001179110-19-003109 · edgar.xml · nonDerivative · entry 4 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,600 Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,400 | $78.25 | $109,550.00 |
DisclosureSEC source: 0001179110-19-003109 · edgar.xml · nonDerivative · entry 3 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,200 Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $78.25 | $23,475.30 |
DisclosureSEC source: 0001179110-19-003109 · edgar.xml · nonDerivative · entry 2 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,600 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 14,663 | $77.23 | $1,132,423.49 |
DisclosureSEC source: 0001179110-19-003109 · edgar.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,900 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 148,895 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002633 · edgar.xml · derivative · entry 2 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,895 Underlying: Common shares · 148,895 shares Expires 2029-02-21 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 49,631 on February 22, 2020, 49,632 on February 22, 2021, and 49,632 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 28,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002633 · edgar.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,563 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 60 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-014233 · edgar.xml · nonDerivative · entry 2 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,158 Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 3,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-014233 · edgar.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,218 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.